retatrutide triple hormone receptor agonist metabolic obesity Media Centre triple hormone receptor agonist retatrutide

M.CarrilhoE.et al

Market Context: As demand has increased, ensuring product quality and medical oversight has become paramount

The NOBILITY trial, a Phase II study, demonstrated that 35% of patients in the obinutuzumab group achieved Complete Renal Response (CRR) at week 52, compared to 23% in the placebo group, although this difference was not statistically significant (P = 0.115)

doi: 10.1001/jama.2020.17023 20 Abou-IsmailMYDiamondAKapoorSArafahYNayakL

The reason for the initial elevated ratio is largely due to low creatinine (in 8/42 children), whereas none had high initial BUN values

This side effect can occur especially after meals or when taking a higher dose